罗氏万赛维服用方法

(Valganciclovir Hydrochloride Tablets) can be used to prevent cytomegalovirus (CMV) infection in patients aged 4 months to 16 years after kidney or heart transplantation. Cytomegalovirus is the primary cause of disease within 6 months of organ transplantation. About 50% to 80% of adults will be infected with the virus, and it may even lie dormant for life. When the autoimmune system is weak, the virus will be relatively active and cause disease. CMV infection can cause complications such as the lungs, kidneys, nervous system, liver, and gastrointestinal tract.

On September 15, 2010, the U.S. Food and Drug Administration (FDA) reminded physicians of the latest recommended dosage of Valcyte, a move to prevent overdose of valganciclovir (Vanceivir) in children undergoing organ transplantation. The latest pediatric recommended dosage is calculated based on the Schwa~z formula for creatinine clearance.

The specific method of taking Roche Vancevir is as follows: The drug should be taken orally with food. For patients with active CMV retinitis, the recommended dose of Vancevir is 900 mg twice a day, and the induction treatment time is 21 days; during the maintenance treatment period, the recommended dose of Vancevir for patients with active or inactive CMV retinitis is 900 mg once a day. For kidney transplant patients, treatment with Vancevir should begin within 10 days after transplantation. The recommended usage is 900 mg once a day, and the treatment time should continue until 200 days after transplantation. For patients who have received solid organ transplants other than kidneys, treatment with Vancevir should begin within 10 days after transplantation. The recommended usage is 900 mg once a day, and the treatment time should continue until 100 days after transplantation.

Founded in 1896 and headquartered in Basel, Switzerland, Roche is one of the world's leading R&D-based health companies in the pharmaceutical and diagnostic fields. Patients need to use Roche correctly to continue to benefit from it.

Recommended hot articles: /newsDetail/90743.html